PTC Therapeutics signs licensing agreement with Roche
SMA is a genetic neuromuscular disorder that causes muscle weakness and is the leading genetic cause of death in infants and toddlers. One in every 10’000 children born is affected with the disorder, which currently has no effective treatment.
HBM BioVentures has invested USD 29 million in PTC over several rounds of financing and is its second largest shareholder. The company has two product candidates at the clinical stage of development and several preclinical and discovery stage programmes. PTC's most advanced product candidate isAtaluren(PTC124®), which is being evaluated in multiple Phase 2 and 3 clinical trials.
In accordance with HBM BioVentures’ valuation principles, the book value of our investment in PTC will not be changed in spite of this positive news.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.